Danish diabetes giant Novo Nordisk (NOV: N) is to fire 3,000 staff and reduce long-term growth projections, in an increasingly challenging pricing environment for insulin.
Shares in the firm dipped after local press reported that management is looking at where the axe should fall, with the intention of announcing the cost-saving measures in the company’s second quarterly report.
The planned cut to long-term growth projections was reportedly due to ‘uncertain and unpredictable’ market factors. In 2016 Novo Nordisk was forced to fire 1,000 if its staff and lower long-term guidance from 15% down to 5%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze